Ribi ImmunoChem liposome contract
Executive Summary
Six-month, $50,000 Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases has been awarded to firm to conduct Phase I studies of its proprietary adjuvants in liposome vaccine delivery systems. The project will include formulating the company's adjuvant products with genetically engineered and synthetic subunit antigens into liposomes. Ribi said it will apply for a $500,000 Phase II research grant if the studies are successful.